NeuroStar® Advanced Therapy Reaches Monumental Milestone of 1.7 Million Treatments in the US Non-drug, non-invasive NeuroStar has become a mainstream option for depression patients, and is now covered by most insurance companies and available in 49 states MALVERN,...
Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer Senior Executive with Global Pharmaceutical Development and Manufacturing Experience WALTHAM, Mass.–(BUSINESS WIRE)–May 29, 2018– Deciphera Pharmaceuticals, Inc....
Preclinical Data Demonstrate That Deciphera Pharmaceuticals’ DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents...
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 Evanston, Ill., March 15, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative...
by Jeff Fryer | Apr 24, 2018 Rallybio Completes $37.0M Series A Financing Rallybio Established by Industry Leaders with $37.0 Million in Series A Financing to Develop Transformative Therapies for Patients with Severe and Rare Diseases FARMINGTON, CT, April 25, 2018 –...
Harpoon Therapeutics Launches Immuno-Oncology Pipeline with Compelling Data from Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and...
Recent Comments